Aldeyra Therapeu Stock Price, News & Analysis

Aldeyra Therapeutics (Nasdaq: ALDX) announced a proposed public offering of its common stock, with underwriters receiving a 30-day option to purchase an additional 15%. The offering aims to raise funds for the development of Aldeyra's lead compound reproxalap, among other product candidates, as well as for working capital and corporate purposes. All shares will be sold by Aldeyra under a previously filed shelf registration statement. Jefferies LLC and SVB Leerink LLC are the joint book-running managers for this offering.

Aldeyra Therapeutics (Nasdaq: ALDX) announced that CEO Todd C. Brady will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference. The chat is scheduled for January 11, 2021, at 6:00 a.m. ET, and will be accessible on the company's website. This event will be archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on developing novel therapies for immune-mediated diseases, with investigational compounds such as reproxalap and ADX-629, targeting reactive aldehyde species in inflammatory diseases.

Aldeyra Therapeutics (Nasdaq: ALDX) announced promising results from the run-in cohort of its Phase 3 TRANQUILITY trial for reproxalap in dry eye disease. The study involved 23 patients, revealing that reproxalap significantly improved ocular dryness and discomfort compared to the vehicle solution (p = 0.001 and p < 0.0001). The drug was also well-tolerated with no adverse safety findings. Aldeyra plans to begin enrollment for the main cohort in February 2021, with results expected in the second half of 2021. This positions reproxalap as a potential first-line treatment for chronic dry eye disease.

Aldeyra Therapeutics (Nasdaq: ALDX) announced a conference call scheduled for January 7, 2021, at 8:00 a.m. ET to discuss top-line results from the Phase 3 TRANQUILITY trial's run-in cohort for dry eye disease. The main cohort of the trial is set to begin enrollment in February 2021, pending tear RASP analysis. Aldeyra is advancing investigational therapies targeting RASP for immune-mediated diseases, including reproxalap and ADX-629, which are undergoing Phase 3 trials.

Aldeyra Therapeutics (Nasdaq: ALDX) has confirmed the antiviral activity of ADX-1612 against SARS-CoV-2, based on preclinical studies conducted in collaboration with the Max Delbrück Center in Berlin. This HSP90 inhibitor shows both antiviral and anti-inflammatory effects in human cells infected with the virus. With additional studies planned, ADX-1612 may also enhance the efficacy of other antiviral drugs. Aldeyra's research emphasizes its commitment to developing therapies for serious viral infections, alongside its ongoing clinical trials for other compounds targeting immune-mediated diseases.

Aldeyra Therapeutics (Nasdaq: ALDX) has initiated Phase 2 clinical trials for ADX-629, a novel orally administered reactive aldehyde species (RASP) inhibitor targeting COVID-19, atopic asthma, and psoriasis. This follows a successful Phase 1 trial showing no adverse events and reduced RASP levels. The COVID-19 trial will enroll around 30 patients to assess safety and efficacy, the asthma trial will involve 12 patients, and the psoriasis study will include 10 patients. The aim is to broaden the application of ADX-629 beyond ocular diseases.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) will participate in two upcoming virtual investor conferences. CEO Todd C. Brady will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 1:10 p.m. ET, available for live streaming on the company's website. Additionally, Aldeyra executives will host one-on-one meetings with institutional investors at the A.G.P./Alliance Global Partners Virtual Healthcare Symposium on November 19, 2020. The firm focuses on innovative therapies for immune-mediated diseases, with lead compounds in clinical trials.

Aldeyra Therapeutics (Nasdaq: ALDX) will present its innovative approaches to ocular disease at the Eyecelerator 2020 Virtual Conference on November 6, 2020. President and CEO Todd C. Brady, M.D., Ph.D., will discuss clinical data on lead drug candidates, including 0.25% reproxalap ophthalmic solution and ADX-2191. Reproxalap is currently in Phase 3 trials for dry eye disease and allergic conjunctivitis, while ADX-2191 focuses on preventing proliferative vitreoretinopathy, a serious retinal disease. The conference aims to foster collaboration in ophthalmic innovation.

Aldeyra Therapeutics, Inc. (ALDX) has scheduled a conference call for November 5, 2020, at 8:00 a.m. ET to discuss its financial results for the quarter ending September 30, 2020. The call will provide an update on the company's corporate activities, focusing on its clinical-stage biotechnology projects aimed at treating immune-mediated diseases. Key compounds include reproxalap, ADX-629, ADX-2191, and ADX-1612, with ongoing Phase 3 trials in dry eye disease and proliferative vitreoretinopathy. A live webcast will be available on the company's investor relations page.